Sarah Romano, Chief Financial Officer at Entero Therapeutics, Inc. (ENTO), sold 727 shares at $0.64 ($465) on 2025-01-06, disclosed to the SEC on 2025-01-08.
Open-market sale of $465 ENTO by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| FWBI | SELL | 2024-04-03 | $317 | — | Filing → |
| FWBI | SELL | 2024-03-19 | $6K | — | Filing → |
| FWBI | SELL | 2024-01-17 | $412 | — | Filing → |